The U.S. Food and Drug Administration in accordance with the longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dosed inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are the propellants that move medication out of the inhaler and into the lungs of patients. Alternative medications that do not contain CFCs are widely available.

Full Text: DOWNLOAD PDF